Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA408889
Max Phase: Preclinical
Molecular Formula: C56H67N9O14
Molecular Weight: 1090.20
Molecule Type: Small molecule
Associated Items:
ID: ALA408889
Max Phase: Preclinical
Molecular Formula: C56H67N9O14
Molecular Weight: 1090.20
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1ccccc1)N(C)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)C(=O)N[C@@H](Cc1cn(C(C)=O)c2ccccc12)C(=O)O
Standard InChI: InChI=1S/C56H67N9O14/c1-5-6-20-41(52(73)62-45(56(78)79)29-38-32-65(34(3)66)46-21-14-13-19-40(38)46)59-53(74)42(30-49(69)70)60-54(75)47(28-36-17-11-8-12-18-36)64(4)63-43(26-35-15-9-7-10-16-35)51(72)57-31-48(68)58-33(2)50(71)61-44(55(76)77)27-37-22-24-39(67)25-23-37/h7-19,21-25,32-33,41-45,47,63,67H,5-6,20,26-31H2,1-4H3,(H,57,72)(H,58,68)(H,59,74)(H,60,75)(H,61,71)(H,62,73)(H,69,70)(H,76,77)(H,78,79)/t33-,41+,42+,43+,44+,45+,47+/m1/s1
Standard InChI Key: DZRXMQMULMXHKQ-GDYSDZBQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1090.20 | Molecular Weight (Monoisotopic): 1089.4807 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Lee YS, Agnes RS, Badghisi H, Davis P, Ma SW, Lai J, Porreca F, Hruby VJ.. (2006) Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists., 49 (5): [PMID:16509592] [10.1021/jm050851n] |
Source(1):